News & Updates

Show Multimedia Only

Mifepristone reduces HbA1c in adults with T2D, hypercortisolism

Treatment with mifepristone significantly reduced HbA_1c levels in patients with difficult-to-control type 2 diabetes (T2D) and hypercortisolism compared with placebo, according to the final results of the CATALYST trial presented at ADA 2025.

Mifepristone reduces HbA1c in adults with T2D, hypercortisolism

7 hours ago

Subcutaneous on par with IV pembrolizumab for NSCLC

21 hours ago by

Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.

Subcutaneous on par with IV pembrolizumab for NSCLC

21 hours ago

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

a day ago

Combination treatment with bevacizumab plus erlotinib appears to work against hereditary leiomyomatosis and renal-cell cancer (HLRCC)-associated or sporadic papillary renal-cell carcinoma, according to an open-label phase II study.

Bevacizumab plus erlotinib shows promise in hereditary, sporadic papillary kidney cancer

a day ago

Ustekinumab improves outcomes in UC patients

a day ago

Treatment with ustekinumab can help patients with ulcerative colitis (UC) achieve clinical and endoscopic outcomes of importance after 12 months, results of a real-world study have shown.

Ustekinumab improves outcomes in UC patients

a day ago

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

16 Jul 2025

Effective antiviral therapy is crucial for achieving sustained viral clearance and improving outcomes in patients with COVID-19, particularly among immunocompromised individuals.

At the recent ESCMID Global 2025 in Vienna, Austria, Ruth Mokgokong, a pharmacologist at Pfizer, UK, presented findings from the EPIC-IC trial, highlighting the benefits of an extended nirmatrelvir-ritonavir regimen in severely immunocompromised patients with symptomatic COVID-19.

Nirmatrelvir-ritonavir shows benefits in immunocompromised individuals with COVID-19

16 Jul 2025

Tirzepatide improves cardiometabolic markers in Chinese adults

15 Jul 2025

Early weight loss associated with the use of tirzepatide may significantly improve cardiometabolic health, particularly in adults achieving a normal BMI by week 52, according to a China study.

Tirzepatide improves cardiometabolic markers in Chinese adults

15 Jul 2025

Cannabis use doubles the risk of dying from heart disease

15 Jul 2025 by

Cannabis use increases the risk of major adverse cardiovascular events (MACE), as shown in a robust meta-analysis, raising serious questions about the assumptions that cannabis use poses little cardiovascular (CV) risk among users.

Cannabis use doubles the risk of dying from heart disease

15 Jul 2025

Expert insights on COVID-19: From vaccination to treatment

15 Jul 2025

Even in 2025, COVID-19 remains a significant global health concern. At a Pfizer-sponsored series of integrated symposia held during the ESCMID Global Congress in Vienna, Austria, leading experts presented the latest data and real-world experiences spanning the COVID-19 care continuum—from vaccination strategies to early antiviral treatment.